Floatz logo

Teclistamab

Peripheral T Cell Lymphoma

CellCentric Ltd.monoclonal_antibodyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

135 Active assets in the Peripheral T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
BeBetter Med Inc
Phase 4BBB
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

Teclistamab is also rated in:

hematopoietic and lymphoid system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
66 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →